Guide
GLP-1-based research has moved faster in the last five years than almost any other area of metabolic science, driven by a simple engineering idea: start with one gut hormone’s receptor, then add a second, then a third. This guide covers how that progression works mechanistically and what the trial evidence actually shows at each step — the receptors involved, not just the drug names.
Quick summary
- GLP-1 and GIP are both incretin hormones released after eating; glucagon is a separate hormone that normally raises blood sugar.
- Single agonists (semaglutide-class) act on GLP-1 alone; dual agonists (tirzepatide-class) add GIP; triple agonists like retatrutide add glucagon.
- Each added receptor changes the mechanism, not just the potency — glucagon in particular shifts the effect from reducing intake to also increasing energy expenditure.
- Cross-trial weight-loss comparisons look like a clean progression, but the trials differ in population and design — the comparison is suggestive, not head-to-head.
- GI side effects scale with receptor count and dose; higher efficacy has tracked with a higher discontinuation rate across this class.
- This catalog carries retatrutide as its GLP-1-pathway compound.
The three receptors, briefly
GLP-1 (glucagon-like peptide-1) is released from intestinal L-cells after eating. Its receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses post-meal glucagon release, and acts on hypothalamic appetite circuits. This is the original mechanism behind the entire drug class, and it is also the primary source of the class’s characteristic nausea.
GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin. Its role is more debated — there is genuine ongoing disagreement in the field about whether GIP receptor agonism or antagonism is the more useful strategy. As an agonist, it is studied for insulin secretion effects and, notably, for anti-emetic activity in the brainstem that may partially offset GLP-1-driven nausea.
Glucagon is not an incretin at all — it is insulin’s counter-regulatory partner, and normally raises blood glucose by driving hepatic glucose output. Deliberately including glucagon receptor activity in a metabolic compound is counterintuitive on its face. The rationale is that glucagon also increases resting energy expenditure and hepatic fat oxidation, adding an energy-output mechanism that the other two receptors do not have; the co-administered insulinotropic activity from GLP-1 and GIP is what offsets the glucose-raising effect.
Single, dual, and triple agonism
Semaglutide and liraglutide are single GLP-1 receptor agonists. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor activity on top of both, making it a triple agonist.
Reported trial results across these compounds show progressively greater mean weight reduction as receptors are added — roughly the mid-teens percent range for the strongest GLP-1-only trials, high-teens to low-20s percent for dual agonism, and Phase 2 retatrutide reporting 24.2% at 48 weeks with Phase 3 TRIUMPH-4 reporting 28.7% at 68 weeks. That progression is real and consistent with the added mechanism.
It is also important to read this correctly: these are separate trials, run in different populations, with different durations and designs — not head-to-head comparisons within a single study. Cross-trial comparison is suggestive of a real trend, not proof of relative superiority, and the research community generally treats it that way.
The pattern in side effects
Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are dose-dependent and consistent across this entire class, and they have generally scaled with added mechanism and dose. Retatrutide’s Phase 2 and Phase 3 programs reported higher GI adverse event rates and higher dose-dependent discontinuation than has been typical for GLP-1-only compounds. This is a real trade-off, not a footnote: greater metabolic effect has tracked with reduced tolerability at the highest doses across this research so far.
Beyond weight: the liver-fat finding
One of the more mechanistically interesting results in this space concerns liver fat. In a retatrutide substudy in participants with metabolic dysfunction-associated steatotic liver disease, liver-fat reduction at 24 weeks was substantially larger than would typically be expected from weight loss alone — consistent with glucagon receptor activity acting directly on hepatic fat oxidation, independent of the appetite-reduction mechanism. If that interpretation holds up, it would represent a genuine mechanistic advantage specific to triple agonism rather than a general property of the class.
Regulatory status
Semaglutide and tirzepatide are FDA-approved for specific indications. Retatrutide remains investigational — not approved by the FDA, EMA, or any other regulator, for any indication, as of this writing. Everything reported about it comes from registered clinical trials conducted under medical supervision.
Frequently asked questions
Is more receptors always better?
Not unconditionally. Added mechanisms have tracked with greater reported weight reduction across trials, but also with a higher rate of GI side effects and discontinuation at the top doses. It is a genuine trade-off, not a strictly upward curve.
Why is glucagon receptor activity counterintuitive here?
Glucagon normally raises blood glucose. Including it deliberately only works because the co-administered GLP-1 and GIP activity is insulinotropic, offsetting that effect while adding an energy-expenditure mechanism the other two receptors lack.
Can I compare weight-loss percentages across these trials directly?
With caution. They are separate trials with different populations and designs, not head-to-head studies. The trend across them is informative but should not be read as a precise ranking.
References
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514–526.
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. Nat Med. 2024.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
Read our full Retatrutide breakdown →
View the Retatrutide product listing →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. Retatrutide is an investigational compound not approved by any regulatory authority. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
